Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how rifaximin 200 mg is processed in the bodies of children aged 6 to 11 years who have acute diarrhea possibly caused by bacteria. The study also aims to assess the safety and effectiveness of rifaximin combined with oral rehydration therapy ORT compared to ORT alone in this pediatric group. This is a phase 4, randomized, open-label trial focusing on treatment outcomes and pharmacokinetics. Participants will be randomly assigned to receive either rifaximin 200 mg tablets three times daily for 3 days combined with ORT or ORT alone according to standard care. The rifaximin group will have blood samples collected on Day 1 and Day 3 to measure drug levels at specific times. All participants will receive ORT as per investigators standard of care and will keep a diary tracking stool frequency, consistency, and symptoms. Participants will attend up to 4 clinic visits during a 5-day treatment period, including screening, Day 1, Day 3 end of treatment, and Day 5 last clinic visit. They will also receive two follow-up phone calls for safety monitoring up to Day 30. Assessments include stool samples to identify bacterial pathogens, blood tests for pharmacokinetics, monitoring for side effects, vital signs, and laboratory tests. The main outcomes measured include rifaximin plasma levels and the proportion of participants achieving clinical cure by Day 5.